从口服药物到靶向治疗:男性不育的APHRODITE时代
本文为观点文章,提出APHRODITE标准(针对因睾丸功能改变、特发性原因导致性腺功能减退和/或不育的男性患者)为男性不育分层和激素治疗提供生物学合理框架,并与IVF卵巢刺激演变类比,主张外源性促性腺激素(LH/hCG和FSH)作为靶向、更早线干预,替代经验性口服药物。
要点
- APHRODITE标准为特发性男性不育提供基于内分泌表型的激素治疗分层框架。
- 选择性雌激素受体调节剂和芳香化酶抑制剂疗效有限,但在特定内分泌特征中仍有作用。
- FSH和LH/hCG基因多态性可能影响治疗反应性,未来需前瞻性试验验证。
核心结论
- APHRODITE系统可能催化男性不育治疗从经验性口服方案向生物学驱动的促性腺激素治疗转变。
研究设计与样本
- 观点文章,未报告系统检索范围或样本量。
主要发现
- 口服克罗米芬和芳香化酶抑制剂常经验性使用而缺乏严格内分泌分型。
- 外源性促性腺激素(LH/hCG和FSH)作为靶向、更早线干预有望改善男性生育结局和疗效。
- FSH和LH/hCG基因多态性可能影响治疗反应性。
关键数值与推荐
- APHRODITE标准用于对不育男性进行分层并定制激素治疗。
- 克罗米芬和芳香化酶抑制剂在特定内分泌特征中保留作用。
临床怎么用
- 临床可依据APHRODITE标准对特发性男性不育进行内分泌分型,考虑将促性腺激素作为更早线靶向治疗。
局限性
- 未来进展取决于应用APHRODITE标准的前瞻性试验及口服药物与注射促性腺激素方案在明确表型患者中的比较分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of idiopathic male infertility has traditionally relied on the empirical use of oral agents such as clomiphene citrate and aromatase inhibitors, often prescribed without rigorous endocrine phenotyping. The newly proposed APHRODITE criteria (Addressing male Patients with Hypogonadism and/or infeRtility Owing to altereD, Idiopathic TEsticular function) introduce a biologically rational framework for stratifying infertile men and tailoring hormonal therapy. This opinion article draws a conceptual parallel with the evolution of ovarian stimulation in IVF, in which exogenous gonadotropins supplanted oral agents due to their superior physiological control and better outcomes. Similarly, the APHRODITE system may catalyze a paradigm shift in male infertility treatment-from empirical, tablet-based regimens to biology-driven gonadotropin therapy. Here, we revisit the hormonal regulation of spermatogenesis, critically appraise the limited efficacy of selective estrogen receptor modulators and aromatase inhibitors, and summarize evidence supporting gonadotropin therapy. We further highlight the potential impact of FSH and LH/hCG genetic polymorphisms on treatment responsiveness. While clomiphene citrate and aromatase inhibitors retain a role in specific endocrine profiles, the new positioning of exogenous gonadotropins-LH/hCG and FSH-as targeted, earlier-line interventions holds promise to improve outcomes and efficacy in male fertility care. Future progress will depend on prospective trials that apply the APHRODITE criteria and on comparative analyses of oral agents versus injectable gonadotropin regimens in well-defined patient phenotypes.
引用
- Esteves SC, Humaidan P. From tablets to targeted therapy: the APHRODITE era in male infertility. Hum Reprod. 2026. PMID: 41863283. doi:10.1093/humrep/deag041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。